GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (STU:E2Z) » Definitions » Other Income (Expense)

Almirall (STU:E2Z) Other Income (Expense) : €-11.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Almirall Other Income (Expense)?

Almirall's other income expense for the Almirall's pretax income for the three months ended in Dec. 2024 was €-7.2 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was €-11.0 Mil.

Almirall Other Income (Expense) Historical Data

The historical data trend for Almirall's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Other Income (Expense) Chart

Almirall Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.48 -99.45 -25.12 -48.61 -11.04

Almirall Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.31 33.40 -36.00 -1.20 -7.24

Almirall Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Almirall  (STU:E2Z) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Almirall Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (STU:E2Z) » Definitions » Other Income (Expense)
Comparable Companies
XMAD:ROVI XMAD:FAE XMAD:RJF XMAD:LAB ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM
Traded in Other Exchanges
ALMe:UK 0O9B:UK ALM:Spain E2Z:Germany ALM:Austria
Address
Ronda General Mitre 151, Barcelona, ESP, 08022
Website
http://www.almirall.es
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall Headlines

No Headlines